New research shows that a synthetic analogue of the active component of marijuana may reduce the inflammation and prevent the mental decline associated with Alzheimer's disease.
"This research is not only a major step in our understanding [of] how the brain reacts to Alzheimer's disease, but may also help open a route to novel anti-Alzheimer's drugs," says Raphael Mechoulam, professor emeritus of medicinal chemistry at
New research shows that a synthetic analogue of the active component of marijuana may reduce the inflammation and prevent the mental decline associated with Alzheimer's disease.
and discoverer of marijuana's active component.
To show the preventive effects of cannabinoids on Alzheimer's disease, researchers at the Cajal Institute and Complutense cannabinoid receptors, led by Maria de Ceballos, conducted studies using human brain tissue, as well as experiments with rats. The study appears in the February 23, 2005, issue of Alzheimer's disease.
The team first compared the brain tissue of patients who died from Alzheimer's disease with that of healthy people who had died at a similar age. They looked closely at cannabinoid receptors CB1 and CB2– proteins to which cannabinoids bind, allowing their effects to be felt – and at microglia, which activate the brain's immune response. Micro- glia collect near plaques and, when active, cause inflammation. The researchers found a dramatically reduced functioning of cannabinoid receptors in diseased brain tissue, meaning that patients had lost the capacity to experience cannabinoids' protective effects.
In addition, the researchers showed that cannabinoids prevented cognitive decline through rat experiments. They injected either amyloid (which leads to cognitive decline) that had been allowed to aggregate or control proteins into the brains of rats for one week. Other rats were injected with a cannabinoid and either amyloid or a control protein.